May. 21 at 5:28 PM
eXoZymes (Nasdaq:
$EXOZ ) CCO Damien Perriman details the NCTx commercialization model after a Cayman Chemical scale-up reached roughly 99% conversion and 99.6% purity.
eXoZymes Inc. (NASDAQ: EXOZ) Chief Commercial Officer Damien Perriman appeared on the Grow Everything podcast, co-hosted by Erum Azeez Khan and Karl Schmieder, to discuss the company’s first spinout, NCTx, and the commercialization model behind its cell-free biomanufacturing platform.
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1.
Perriman explained why eXoZymes launched NCTx as a dedicated vehicle for NCT while keeping eXoZymes focused on what it does best: developing better ways to manufacture difficult-to-access molecules with real commercial potential. He outlined a supplement-first path for NCT, citing an established GRAS pathway and a potentially faster route to market, with a longer pharmaceutical track running in parallel.
He also pointed to recent third-party validation with Cayman Chemical, which independently transferred and ran the NCT process at 100-fold scale, reaching approximately 99% conversion and 99.6% purity on the first attempt. Perriman described the result as a proof point that the platform can support tech transfer and external manufacturing.
On the episode, Perriman put it this way: “When our process performs successfully in someone else’s hands at scale, it reinforces that cell-free biomanufacturing can be a practical commercial platform.”
Watch the full interview here: https://youtu.be/eDsyoZzwOJM?si=5GgoaTuGoyZQykyJ
Read more at https://exozymes.com/blog/grow-everything-podcast-perriman-2026
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
eXoZymes is a Los Angeles, California-based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to transform abundant feedstock into high-value nutraceuticals and novel medicines. The company is currently focused on products including NCT, non-intoxicating cannabinoids, and sustainable aviation fuel.
eXoZymes is led by an experienced management team including Michael Heltzen, CEO; Damien Perriman, CCO; Dr. Tyler Korman, CSO and Co-founder; Dr. Paul Opgenorth, VP of Development and Co-founder; Fouad Nawaz, VP of Finance; Lasse H. Görlitz, VP of Communications; and Amy Lunzer, Chief of Staff.
Learn more at https://exozymes.com. For investor inquiries, visit https://exozymes.com/investor.
Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser.
$DNLI,
$TWST,
$DNA,
$ARKG